CDT Equity Inc. (CDT)
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
CDT Equity Inc.
| Form | Description | Links | |
|---|---|---|---|
| 424B3 | |||
| 10-Q | |||
| 424B3 | |||
| 8-K | |||
| 424B3 | |||
| 8-K | |||
| 13D/A | |||
| 424B3 | |||
| 8-K | |||
| 424B3 | |||
| 13G/A | |||
| DEF 14A | |||
| 4 | |||
| 4/A | |||
| 13D/A | |||
| 3 | |||
| 8-K | |||
| PRE 14A | |||
| 424B3 | |||
| 8-K | |||
| 13G/A | |||
| 13G | |||
| 13G/A | |||
| 13G/A | |||
| 424B3 |
1-25 of 375 filings
Recent SEC filings with analysis
- 424B3CDT Equity Inc.
- 10-QCDT Equity reported a Q3 net loss of $4.6 million and a nine-month net loss of $13.3 million, with cash of just $1.7 million against an accumulated deficit of…
- 424B3CDT Equity Inc.
- 424B3Former CDT Equity CEO Dr.
- 424B3CDT Equity Inc.
- 424B3CDT Equity Inc.
- 8-KCDT Equity entered an Evaluation Agreement with Manoira Corporation on October 22, 2026, under which Manoira will assess CDT's clinical-stage compounds AZD1656…
- 424B3CDT Equity Inc.